insulin secretagogues

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patient       DPP-4 inhibitorsDPP-4 inhibitors add on current treatmentDPP-4 inhibitors add on insulinDPP-4 inhibitors add on METDPP-4 inhibitors add on MET+SUDPP-4 inhibitors add on SUDPP-4 inhibitors add on TZDDPP-4 inhibitors in combinationDPP-4 inhibitors monotherapymeglitinides (glinides)sulfonylurea G1sulfonylurea G1 add on METsulfonylureas G2sulfonylureas G2 add on METsulfonylureas G3 add on insulinsulfonylureas G3 add on METsulfonylureas G3 monotherapy alogliptingliclazideglimepirideglimeripideglipizideglyburidelinagliptinmitiglinidenateglinidepioglitazonerepaglinide saxagliptinsitagliptinvildagliptin vs alpha-glucosidase inhibitorvs placebovs placebo or controlvs active treatmentvs biguanidesvs gliclazidevs SUvs Sulfonylureavs TZD      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	Adverse events leading to treatment discontinuation (23)All cause death (3)myocardial infarction (fatal and non fatal) (3)stroke (fatal and non fatal) (3)cardiovascular events (3)Cardiovascular death (3) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	Adverse events leading to treatment discontinuation	All cause death
diabetes type 2
alogliptin
Seino, 2011      NCT	alogliptin					-
Seino, 2011	alogliptin					-
Bosi , 2011      NCT	alogliptin					-
Kaku, 2011	alogliptin					-
Rosenstock, 2010      NCT	alogliptin					-
Rosenstock, 2009      NCT	alogliptin					-
Pratley, 2009      NCT	alogliptin					-
Pratley, 2009      NCT	alogliptin					-
DeFronzo , 2008      NCT	alogliptin					-
EXAMINE, 2011        NCT	alogliptin	placebo				negative
Nauck, 2009      NCT	alogliptin	placebo (add on MET)			Low risk of bias	negative
gliclazide
Ristic, 2006	gliclazide	nateglinide (add on MET)			Low risk of bias	-
Matthews, 2005	gliclazide	pioglitazone (add on MET)			Low risk of bias	-
Khanolkar, 2008	gliclazide	rosiglitazone (add on MET)				-
glimepiride
Charpentier, 2001	glimepiride monotherapy	metformin			Low risk of bias	-
glimeripide
Study 201 (Goldberg), 1996	glimepiride	placebo			Low risk of bias	-
Schade, 1998	glimepiride	placebo			Low risk of bias	-
Rosenstock, 1996	glimepiride	placebo			Low risk of bias	-
Luis Bautista, 2003	glimepiride	placebo			Low risk of bias	-
Kaneko, 1993	glimepiride	placebo				-
Study 202	glimepiride	placebo				-
Riddle, 1994	glimepiride	placebo (add on insulin)				-
LEAD-2 (Nauck) Sulf vs pbo, 2009      NCT	glimepiride	placebo (add on MET)			Low risk of bias	-
Charpentier, 2001	glimepiride	placebo (add on MET)			Low risk of bias	negative
Draeger, 1996	glimepiride	glibenclamide			Low risk of bias	-
Protocol 311	glimepiride	glibenclamide				-
Charpentier (301F)	glimepiride	gliclazide				-
Inukai, 2005	glimepiride	gliclazide or glibenclamide				-
Sonnenberg, 1997	glimepiride od	glimepiride bid				-
Clark (301), 1997	glimepiride	glipizide				-
Dills, 1996	glimepiride	glyburide			Low risk of bias	-
glipizide
Goldstein	glipizide	control (add on MET)				-
Rosenstock, 1993	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide				-
Birkeland, 1994	glipizide	glyburide			Low risk of bias	-
Simonson, 1997	glipizide	placebo			Low risk of bias	-
Testa, 1998	glipizide	placebo				-
Feinglos, 2005	glipizide GITS	placebo (add on MET)			Low risk of bias	-
Nauck, 2007	glipizide	sitagliptin (add on MET)				-
glyburide
Hermann, 1991	glibenclamide	c (add on MET)				-
DeFronzo, 1995	glyburide	c (add on MET)			Low risk of bias	-
Erle, 1999	glyburide	c (add on MET)				-
Marre (ass), 2002	glibenclamide	control (add on MET)			Low risk of bias	-
Tosi, 2003	glibenclamide	control (add on MET)			Low risk of bias	-
Blonde, 2002	glyburide	control (add on MET)			Low risk of bias	-
Garber, 2003	glyburide	control (add on MET)				-
Garber, 2002	glyburide	placebo			Low risk of bias	-
Vray, 1995	glyburide	placebo			Low risk of bias	-
Garber, 2006	glibenclamide	rosiglitazone (add on MET)			Low risk of bias	-
linagliptin
Forst, 2010      NCT	linagliptin				Low risk of bias	-
CAROLINA, 2012      NCT	linagliptin	glimepiride			Low risk of bias	suggesting
Gallwitz, 2012      NCT	linagliptin	glimepiride (add on MET)			Low risk of bias	-
Owens      NCT	linagliptin	Metformin + sulfonylurea				-
Del Prato      NCT	linagliptin	placebo			Low risk of bias	-
Taskinen      NCT	linagliptin	placebo (add on MET)				-
Gomis, 2011      NCT	linagliptin	placebo (add on pioglitazone)				-
Lewin, 2010    NCT	linagliptin	placebo (add on SU)			Low risk of bias	-
mitiglinide
Gao      NCT	mitiglinide	nateglinide			Low risk of bias	-
Kumashiro, 2007	mitiglinide	on top insulin glargine				-
Kaku, 2009	mitiglinide	placebo (on top pioglitazone)				-
nateglinide
Marre, 2002	nateglinide	placebo			Low risk of bias	-
Horton, 2000	nateglinide	placebo			Low risk of bias	-
Hanefeld, 1990	nateglinide	placebo			Low risk of bias	-
Saloranta, 2002	nateglinide	placebo			Low risk of bias	-
Mari, 2005	nateglinide	placebo				-
Moses, 2001	nateglinide	placebo			Low risk of bias	-
Goldberg, 1998	repaglinide	placebo			Low risk of bias	-
Jovanovic, 2000	repaglinide	placebo			Low risk of bias	-
Bech, 2003	repaglinide	placebo			Low risk of bias	-
Li, 2009	nateglinide	repaglinide				-
Li, 2007	nateglinide	repaglinide				-
Ristic, 2006	nateglinide	gliclazide (add on MET)			Low risk of bias	-
repaglinide
Moses, 1999	repaglinide	control (add on MET)			Exploratory	-
Landgraf, 1999	repaglinide	glibenclamide			Low risk of bias	-
Marbury, 1999	repaglinide	glibenclamide				-
Wolffenbuttel, 1999	repaglinide	glibenclamide			Low risk of bias	-
Madsbad, 2001	repaglinide	glipizide			Low risk of bias	-
Lund, 2007	repaglinide	metformin			Low risk of bias	-
Raskin, 2001	repaglinide	on top pioglitazone				-
Raskin, 2001	repaglinide	on top rosiglitazone				-
Raskin, 2000	repaglinide	on top troglitazone				-
Chuang, 1999	repaglinide	placebo				-
Goldberg, 1998	repaglinide	placebo			Exploratory	-
Jovanovic, 2000	repaglinide	placebo			Low risk of bias	-
Landin-Olsson, 1999	repaglinide	placebo (on top bedtime NPH-insulin)				-
saxagliptin
Kawamori, 2012        NCT	saxagliptin					-
Forst, 2011	Saxagliptin					-
Fonseca, 2012      NCT	saxagliptin					-
Nowicki, 2011      NCT	saxagliptin					-
Yang, 2011      NCT	saxagliptin					-
Nowicki, 2011      NCT	saxagliptin					-
Göke, 2010	saxagliptin					-
Scheen , 2010	saxagliptin					-
Stenlöf , 2010	Saxagliptin					-
CV181-040      NCT	saxagliptin + glyburide	glyburide uptitration				-
CV181-085    NCT	saxagliptin plus metformin XR 1500mg	metformin up to 2000mg				-
SAVOR-TIMI 53, 2013        NCT	saxagliptin	placebo				negative
saxgliptin, renal study	saxagliptin	placebo (add on current treatment)				-
CV181-057    NCT	saxagliptin	placebo (add on insulin)				-
DeFronzo, 2009      NCT	saxagliptin	placebo (add on MET)				negative
Jadzinsky, 2009      NCT	saxagliptin	placebo (add on MET)				-
CV181-066    NCT	saxagliptin	placebo (add on MET)				-
CV181-080    NCT	saxagliptin	placebo (add on MET)				-
Hollander      NCT	saxagliptin	placebo (add on TZD)				-
Rosenstock, 2008    NCT	saxagliptin	placebo (monotherapy)				-
CV181-011      NCT	saxagliptin	placebo (monotherapy)				-
CV181-038    NCT	saxagliptin	placebo (monotherapy)				-
CV181-041    NCT	saxagliptin	placebo (monotherapy)				-
saxagliptin vs sitagliptin	saxagliptin	sitagliptin (add on MET)				-
saxagliptin	saxagliptin	glipizide			Low risk of bias	-
sitagliptin
Stafford , 2011      NCT	sitagliptin					-
Reasner, 2011      NCT	sitagliptin	control (add on MET)				-
Arechavaleta, 2011      NCT	sitagliptin	glimepiride (add on MET)			Low risk of bias	-
Aschner, 2010      NCT	sitagliptin monotherapy	metformin			Low risk of bias	-
Derosa , 2010	sitagliptin+pio	metformin+pio				-
Goldstein, 2007      NCT	sitagliptin	placebo				negative
Hanefeld, 2007	sitagliptin	placebo				negative
Scott* (sit vs pbo), 2007	sitagliptin 50mg bid monotherapy	placebo				negative
Aschner, 2006      NCT	sitagliptin monotherapy	placebo				negative
Nonaka, 2008      NCT	sitagliptin monotherapy	placebo			Low risk of bias	negative
Raz, 2006	sitagliptin monotherapy	placebo				negative
Barzilai, 2011      NCT	sitagliptin monotherapy	placebo			Low risk of bias	-
Mohan , 2009	sitagliptin monotherapy	placebo			Low risk of bias	-
Chan, 2008	sitagliptin monotherapy	placebo			Low risk of bias	-
Vilsbøll, 2010      NCT	sitagliptin	placebo (add on insulin+/-MET)			Low risk of bias	-
Charbonnel, 2006      NCT	sitagliptin	placebo (add on MET)				negative
Nauck, 2007          NCT	sitagliptin	placebo (add on MET)				negative
Scott** (sit vs pbo on top met), 2007	sitagliptin	placebo (add on MET)				negative
raz, 2008      NCT	sitagliptin	placebo (add on MET)				-
Rosenstock , 2006      NCT	sitagliptin	placebo (add on PIO)			Low risk of bias	-
Rosenstock (sit on top pio vs pbo), 2006      NCT	sitagliptin	placebo (on top PIO)				suggesting
Hermansen, 2007	sitagliptin	placebo (on-top glimepiride+/- metformine)				negative
Rigby , 2010	sitagliptin	rosiglitazone (add on MET)				-
Al Sifri, 2011	sitagliptin	Sulphonylurea (on top MET)				-
Iwamoto , 2010	sitagliptin monotherapy	voglibose			Low risk of bias	-
Scott* (sit vs glipi), 2007	sitagliptin 50mg bid monotherapy	glipizide			Low risk of bias	-
Goldstein (sit vs met), 2007	sitagliptin	metformin				-
Goldstein (sit+met vs met), 2007	sitagliptin	metformin				-
Pérez-Monteverde, 2011      NCT	sitagliptin	pioglitazone			Low risk of bias	-
vildagliptin
NCT00101673      NCT	vildagliptin					-
Pan, 2008      NCT	vildagliptin monotherapy	acarbose			Low risk of bias	-
Foley, 2009      NCT	vildagliptin monotherapy	gliclazide			Low risk of bias	-
Filozof, 2009      NCT	vildagliptin	gliclazide (add on MET)			Low risk of bias	-
Matthews , 2010	vildagliptin	glimepiride (add on MET)			Low risk of bias	-
CLAF237A 23104    NCT	vildagliptin + MET	MET				-
Schweizer, 2009      NCT	vildagliptin	metformin				-
Mimori, 2006	vildagliptin	placebo				-
Scherbaum [2], 2008          NCT	vildagliptin	placebo			Low risk of bias	negative
Rosenstock, 2008      NCT	vildagliptin	placebo			Low risk of bias	-
NCT00351832    NCT	vildagliptin	placebo				-
Dejager [1], 2007      NCT	vildagliptin monotherapy	placebo			Low risk of bias	negative
Pi-Sunyer, 2007      NCT	vildagliptin monotherapy	placebo			Low risk of bias	suggesting
Pratley, 2006	vildagliptin monotherapy	placebo			Low risk of bias	negative
Ristic, 2005	vildagliptin monotherapy	placebo				negative
Foley, 2011      NCT	vildagliptin monotherapy	placebo				-
Kikuchi, 2009	vildagliptin monotherapy	placebo				-
Ahren, 2009    NCT	vildagliptin monotherapy	placebo				-
Lukashevich , 2011	vildagliptin	placebo (add on current therapy)				-
Kikuchi, 2010      NCT	vildagliptin	placebo (add on glimepiride)			Low risk of bias	-
Fonseca, 2007      NCT	vildagliptin	placebo (add on insulin)			Low risk of bias	suggesting
Fonseca , 2008	vildagliptin	placebo (add on insulin)				-
Ahren, 2004	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Bosi, 2007      NCT	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Goodman, 2009	vildagliptin	placebo (add on MET)			Low risk of bias	negative
Bosi, 2009      NCT	vildagliptin	placebo (add on MET)				-
NCT00728351    NCT	vildagliptin	placebo (add on MET)				-
NCT00822211    NCT	vildagliptin	placebo (add on MET)				-
NCT00494884 (Wollmer)    NCT	vildagliptin	placebo (add on MET)				-
NCT00396071    NCT	vildagliptin	placebo (add on MET)				-
Garber, 2008      NCT	vildagliptin	placebo (add on SU)			Low risk of bias	-
Garber, 2007      NCT	vildagliptin	placebo (on top pioglitazone)				negative
Rosenstock, 2009    NCT	vildagliptin	rosiglitazone			Low risk of bias	-
Ferrannini, 2009      NCT	vildagliptin	Sulfonylurea (add on to MET)			Low risk of bias	suggesting
GALIANT (Blonde), 2009      NCT	vildagliptin	TZD (add on MET)				-
NCT00368134    NCT	vildagliptin	voglibose				-
Iwamoto, 2010	vildagliptin	voglibose			Low risk of bias	-
Schweizer, 2007        NCT	vildagliptin	metformin				negative
Goke, 2008	vildagliptin	metformin				-
Rosenstock** (vilda vs pio), 2007      NCT	vildagliptin monotherapy	pioglitazone			Low risk of bias	-
Bolli, 2008        NCT	vildagliptin	pioglitazone (add on MET)			Low risk of bias	negative
Rosenstock** (vilda + pio vs pio), 2007      NCT	vildagliptin	placebo (add on TZD)			Low risk of bias	negative
Rosenstock* (vilda vs rosi), 2007        NCT	vildagliptin	rosiglitazone			Low risk of bias	-